Compare JetBlue Airways Corporation (JBLU) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Moderna, Inc. — how do they compare? JetBlue Airways Corporation trades at $3.85 (market cap $1.48B), while Moderna, Inc. trades at $221.1 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 53.1× JetBlue Airways Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Moderna, Inc. for 59 Days on average.
| JBLU | MRNA | |
|---|---|---|
Market Cap | $1.48B | $78.65B |
Volume | 30,275,693 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $6.46 | $203.46 |
52-Week Low | $3.92 | $22.36 |
Typical Hold Time | 44 Days | 59 Days |
Enterprise Value | $8.84B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.86, down 2.77% today, reflecting persistent bearish technical signals and weak earnings. The company reported a net loss of $602 million in 2025, with negative profit margins and declining revenue. Recent news includes route expansion to Colombia but also reduced capacity guidance due to weather and fuel costs. Technical indicators are bearish, with the stock trading near support levels.
The outlook remains challenging with high debt levels and consistent losses. Analyst consensus is mixed but leans hold, with a $5.89 price target suggesting potential upside if operational improvements materialize. Key risks include elevated fuel prices, competitive pressure, and macroeconomic sensitivity. Investment appeal is limited to speculative recovery bets amid ongoing fundamental headwinds.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
